See more : Urbanimmersive Inc. (UBMRF) Income Statement Analysis – Financial Results
Complete financial analysis of Galera Therapeutics, Inc. (GRTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Galera Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- TheraVet SA (ALVET.PA) Income Statement Analysis – Financial Results
- Wave Power Technology Inc. (6895.TWO) Income Statement Analysis – Financial Results
- SigmaRoc plc (SRC.L) Income Statement Analysis – Financial Results
- IAC InterActive Corp. (IAC) Income Statement Analysis – Financial Results
- Telefonaktiebolaget LM Ericsson (publ) (ERIBR.HE) Income Statement Analysis – Financial Results
Galera Therapeutics, Inc. (GRTX)
About Galera Therapeutics, Inc.
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 259.00K | 114.00K | 778.00K | 368.00K | 267.00K | 127.00K | 84.00K |
| Gross Profit | -259.00K | -114.00K | -778.00K | -368.00K | -267.00K | -127.00K | -84.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 24.12M | 31.01M | 52.42M | 54.85M | 42.33M | 18.66M | 20.59M |
| General & Administrative | 22.84M | 20.21M | 20.95M | 15.71M | 8.36M | 5.59M | 3.50M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 22.84M | 20.21M | 20.95M | 15.71M | 8.36M | 5.59M | 3.50M |
| Other Expenses | 0.00 | -11.07M | -7.17M | -3.68M | -1.25M | 0.00 | 0.00 |
| Operating Expenses | 46.95M | 51.23M | 73.37M | 70.55M | 50.69M | 24.26M | 24.09M |
| Cost & Expenses | 46.95M | 51.23M | 73.37M | 70.55M | 50.69M | 24.26M | 24.09M |
| Interest Income | 9.82M | 506.00K | 32.00K | 1.17M | 1.82M | 606.00K | 193.00K |
| Interest Expense | 0.00 | 11.57M | 7.19M | 4.88M | 3.03M | 220.00K | 0.00 |
| Depreciation & Amortization | 259.00K | 114.00K | 778.00K | 368.00K | 267.00K | 127.00K | 84.00K |
| EBITDA | -46.69M | -50.61M | -72.56M | -69.01M | -50.69M | -23.52M | -23.82M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -46.95M | -51.23M | -73.37M | -70.55M | -50.69M | -24.26M | -24.09M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -12.13M | -11.07M | -7.17M | -3.68M | -1.25M | 356.00K | 189.00K |
| Income Before Tax | -59.08M | -62.29M | -80.53M | -74.23M | -51.94M | -23.90M | -23.91M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -70.00K | 7.19M | -16.00K | -9.00K | -223.00K | -360.00K |
| Net Income | -59.08M | -62.22M | -87.73M | -74.22M | -51.93M | -23.68M | -23.55M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.33 | -2.30 | -3.40 | -2.98 | -2.09 | -1.22 | -1.55 |
| EPS Diluted | -1.33 | -2.30 | -3.40 | -2.98 | -2.09 | -1.22 | -1.55 |
| Weighted Avg Shares Out | 44.55M | 27.09M | 25.79M | 24.87M | 24.81M | 19.36M | 15.22M |
| Weighted Avg Shares Out (Dil) | 44.55M | 27.09M | 25.79M | 24.87M | 24.81M | 19.36M | 15.22M |
Galera Announces Board Approval of Complete Liquidation and Dissolution
Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates
Galera Adopts Limited Duration Stockholder Rights Agreement
Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates
Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
Galera Announces Receipt of Type A Meeting Minutes and Strategic Update
Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem
Top 5 Health Care Stocks That May Explode In Q3 - BioVie (NASDAQ:BIVI), Galera Therapeutics (NASDAQ:GRTX)
All You Need to Know About Galera Therapeutics, Inc. (GRTX) Rating Upgrade to Buy
3 Biotech Stocks Poised to Beat Q2 Earnings Estimates
Source: https://incomestatements.info
Category: Stock Reports